1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Startup Alzheon revives tramiprosate for Alzheimer's with license for prodrug

 
• By Mandy Jackson

Lexington, Massachusetts-based startup Alzheon raised an undisclosed amount of private capital from two unidentified private investors to develop ALZ-801, a prodrug of the well-known Alzheimer's drug tramiprosate (Alzhemed), which failed in Phase III clinical trials.

Lexington, Massachusetts-based startup Alzheon raised an undisclosed amount of private capital from two unidentified private investors to develop ALZ-801, a prodrug of the well-known Alzheimer's drug tramiprosate (Alzhemed), which failed in Phase III clinical trials.

Alzheon licensed ALZ-801 (BLU8499) and associated intellectual property from Bellus Health, whose predecessor Neurochem conducted the ill-fated tramiprosate trials (scripintelligence.com, 29 August 2007)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

More from Therapy Areas

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

 
• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.